Pudafensine
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 4, 2021 (NCT04969666)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc2ccc(O[C@@H]3C[C@H]4CC[C@@H](C3)N4)cc2oc1=O- Mol. weight
- 301.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068030 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04969666 | Phase 2 | Aug 4, 2021 | Initiator Pharma, MAC UK |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Initiator Pharma | For profit | 1 | 1 | 1 | 2021 |
| MAC UK | For profit | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1